Symptoms of mental disorders and oral contraception use: A systematic review and meta-analysis

IF 6.5 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Mathilda Z. Kraft , Philine Rojczyk , Thomas Weiss , Birgit Derntl , Zora Kikinis , Ilona Croy , Carina Heller
{"title":"Symptoms of mental disorders and oral contraception use: A systematic review and meta-analysis","authors":"Mathilda Z. Kraft ,&nbsp;Philine Rojczyk ,&nbsp;Thomas Weiss ,&nbsp;Birgit Derntl ,&nbsp;Zora Kikinis ,&nbsp;Ilona Croy ,&nbsp;Carina Heller","doi":"10.1016/j.yfrne.2023.101111","DOIUrl":null,"url":null,"abstract":"<div><p>Worldwide, over 150 million adolescent and adult women use oral contraceptives (OC). An association between OC-use and the emergence of symptoms of mental disorders has been suggested. This systematic review and meta-analysis provide an overview of published research regarding symptoms of mental disorders in association with OC-use, factoring the influence of OC types, age of first-use, duration of OC-intake, and previous diagnoses of mental disorders. A systematic literature search was conducted between June-July 2022. 22 studies were included. While most found no significant OC-use effects on mental symptoms, some hinted at OCs as a potential risk. The existing evidence regarding the potential link between progestin-only OC-use and an elevated risk of mental symptoms in comparison to combined OC-use remains inconclusive. However, due to emerging indications suggesting that the formulation of OC might play a role in mental health outcomes, this topic warrants further investigation. Moreover, indications of an increased risk for depressive symptoms in adolescent OC-users should be noted. Hence, while general population effects seem unlikely, they cannot be completely disregarded. The decision on OC-use should depend on the patient's medical history and should be re-evaluated regularly.</p></div>","PeriodicalId":12469,"journal":{"name":"Frontiers in Neuroendocrinology","volume":"72 ","pages":"Article 101111"},"PeriodicalIF":6.5000,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0091302223000596/pdfft?md5=5af9066c6f4133c8da5b56b6ae49e1ab&pid=1-s2.0-S0091302223000596-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091302223000596","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Worldwide, over 150 million adolescent and adult women use oral contraceptives (OC). An association between OC-use and the emergence of symptoms of mental disorders has been suggested. This systematic review and meta-analysis provide an overview of published research regarding symptoms of mental disorders in association with OC-use, factoring the influence of OC types, age of first-use, duration of OC-intake, and previous diagnoses of mental disorders. A systematic literature search was conducted between June-July 2022. 22 studies were included. While most found no significant OC-use effects on mental symptoms, some hinted at OCs as a potential risk. The existing evidence regarding the potential link between progestin-only OC-use and an elevated risk of mental symptoms in comparison to combined OC-use remains inconclusive. However, due to emerging indications suggesting that the formulation of OC might play a role in mental health outcomes, this topic warrants further investigation. Moreover, indications of an increased risk for depressive symptoms in adolescent OC-users should be noted. Hence, while general population effects seem unlikely, they cannot be completely disregarded. The decision on OC-use should depend on the patient's medical history and should be re-evaluated regularly.

精神障碍症状与口服避孕药的使用:一项系统回顾和荟萃分析。
全世界有超过1.5亿青少年和成年妇女使用口服避孕药(OC)。使用强迫症与精神障碍症状的出现之间存在关联。本系统综述和荟萃分析概述了已发表的与使用强迫症相关的精神障碍症状的研究,并考虑了强迫症类型、首次使用年龄、服用强迫症持续时间和既往精神障碍诊断的影响。在2022年6月至7月期间进行了系统的文献检索。纳入了22项研究。虽然大多数人没有发现使用强迫症对精神症状的显著影响,但有些人暗示强迫症是一种潜在的风险。与联合使用孕激素相比,仅使用孕激素与精神症状风险增加之间的潜在联系的现有证据仍然没有定论。然而,由于新出现的迹象表明OC的形成可能在心理健康结果中发挥作用,这一主题值得进一步研究。此外,应该注意青少年强迫症使用者抑郁症状风险增加的迹象。因此,尽管总体群体效应似乎不太可能,但也不能完全忽视它们。使用oc的决定应取决于患者的病史,并应定期重新评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Neuroendocrinology
Frontiers in Neuroendocrinology 医学-内分泌学与代谢
CiteScore
13.30
自引率
6.80%
发文量
62
审稿时长
68 days
期刊介绍: Frontiers in Neuroendocrinology (FIN) publishes a wide range of informative articles including comprehensive reviews, systematic reviews, opinion pieces, and meta-analyses. While the majority of reviews are invited, we also embrace unsolicited reviews and meta-analyses, as well as proposals for thematic special issues, provided they meet our rigorous quality standards. In addition, we encourage authors to submit commentaries that concisely present fresh ideas or offer further analysis to delve deeper into the implications of an article published in our journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信